Abstract: Compositions and methods are provided for inhibiting or treating the early and established stages of inflammatory diseases by administration of an effective dose of the desethylhydroxychloroquine (DHCQ). A benefit of the methods is the ability to deliver a dose of agent that is effective in treating inflammation while sparing the individual from retinal toxicity.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
April 11, 2017
Assignees:
The Board of Trustees of the Leland Stanford Junior University, The United States of America as Represented by the Department of Veterans Affairs
Inventors:
William H. Robinson, Jeremy Sokolove, Qian Wang
Abstract: It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.
Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.
Abstract: The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of the pharmaceutically acceptable salts thereof for treating cancer and particularly in preventing and/or treating cancerous metastases.
Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.
Abstract: Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
Type:
Grant
Filed:
August 5, 2016
Date of Patent:
March 14, 2017
Assignee:
Synergistic Therapeutics, LLC
Inventors:
Anthony H. Salce, Jr., William F. Greenwood, Shivsankar Misir
Abstract: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP18?) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl) amine structure.
Abstract: An aqueous microbicidal composition having two components. The first component is a nonionic surfactant with structure: R1O(CH2CH(CH3)O)5(CH2CH2O)9H, where R1 is a C8 alkyl group. The second component is phenoxyethanol. The weight ratio of the nonionic surfactant to phenoxyethanol is from 1:1 to 1:18.2766.
Type:
Grant
Filed:
October 2, 2014
Date of Patent:
March 7, 2017
Assignees:
DOW GLOBAL TECHNOLOGIES LLC, ROHM AND HAAS COMPANY
Inventors:
Usha Gandhi, Christine McInnis, Kiran Pareek, Paul O. Schook, Nigel G. Watson, Terry Michael Williams, Bei Yin
Abstract: Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.
Abstract: The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.
Type:
Grant
Filed:
May 9, 2016
Date of Patent:
March 7, 2017
Assignees:
Jazz Pharmaceuticals International III Limited, SK Biopharmaceuticals Co., Ltd.
Inventors:
Moise A. Khayrallah, Gary Bream, Stephen E. Butts
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
Type:
Grant
Filed:
October 21, 2014
Date of Patent:
February 28, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li
Abstract: The present invention relates to compounds of formula (I), and salts thereof and the pharmaceutical composition containing them in treatment of various diseases, as allergic rhinitis where R1 and R2 are, independently, hydrogen, halogen, C1_3 alkyl or C1-3alkoxy; R3 is phenyl optionally substituted by R4 and R5 which are, independently hydrogen, halogen, C1-3 alkyl, C1-3-alkoxy, fluoro-, difluoro- and trifluoromethyl, nitrile group, N,N-diC1-3alkyl-amide, carboC1-3 alkoxy or C1-3alkylsulphone groups; R3 is pyridyl group containing nitrogen at various positions in the benzene ring, n is one of the integers 1 or 2.
Type:
Grant
Filed:
September 30, 2013
Date of Patent:
February 21, 2017
Assignee:
Polfarmex S.A.
Inventors:
Piotr Kopczacki, Mieczyslaw Wosko, Jaroslaw Walczak, Krzysztof Walczynski
Abstract: The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37° C.±0.5° C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Abstract: The present invention provides a method of suppressing mast cell differentiation and/or itch in the skin of a subject, comprising topically administering to the skin in need thereof an effective amount of fucoxanthin or a derivative thereof.
Abstract: The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.
Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.
Type:
Grant
Filed:
June 22, 2015
Date of Patent:
January 24, 2017
Assignees:
Research & Business Foundation Sungkyunkwan University, Ltd., Gyeonggi Institute of Science & Technology Promotion
Inventors:
Kye Won Park, Nojoon Song, Suk Chan Lee, Jin-Mo Ku
Abstract: Disclosed is the therapeutic potential of Calebin A for osteoporosis (bone loss) caused by aging or chronic disease conditions like cancer. Calebin A is shown to down modulate osteoclastogenesis induced by receptor activator of nuclear factor (NF)-?B ligand (RANKL) signalling thereby having therapeutic potential for osteoporosis.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
January 10, 2017
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam
Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Type:
Grant
Filed:
June 3, 2013
Date of Patent:
January 10, 2017
Assignee:
Pharmacyclics LLC
Inventors:
Norbert Purro, Mark Smyth, Erick Goldman, David D. Wirth
Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
January 10, 2017
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION
Inventors:
Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang